In addition, the NCCN Panel recommends that metastatic disease at presentation or first recurrence of disease should be biopsied so that the ER, PR and HER2 status is determined as a part of the workup for patients with recurrent or stage IV disease (Arslan et al., 2011; Gradishar et al., 2018). This evidence concerns the gene PGR and metastatic neoplasm.